Women's Cancer Study Group GmbH — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Women's Cancer Study Group GmbH appears in 20 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials20

Recruiting shown5

Roles1

SourceClinicalTrials.gov

Clinical trials

20 shown

Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBCNCT07242352 · lead sponsor · 2026-04-29

Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based TreatmentNCT07281833 · lead sponsor · 2025-11-27

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)NCT06081244 · lead sponsor · 2024-10-10

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerNCT05704829 · lead sponsor · 2024-02-05

PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFSNCT05792150 · lead sponsor · 2022-12-07

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast CancerNCT07178730 · lead sponsor · 2026-08-30

NOT_YET_RECRUITING

Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBCNCT04565054 · lead sponsor · 2020-09-02

ACTIVE_NOT_RECRUITING

A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)NCT03988036 · lead sponsor · 2020-08-18

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBCNCT04055493 · lead sponsor · 2019-07-02

ACTIVE_NOT_RECRUITING

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)NCT02269813 · lead sponsor · 2015-04-01

A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low ResponseNCT02214381 · lead sponsor · 2014-07-01

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT ProtocolNCT01817452 · lead sponsor · 2014-03-01

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast CancerNCT01891357 · lead sponsor · 2013-09-30

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast CancerNCT01815242 · lead sponsor · 2013-06-01

A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.NCT01745965 · lead sponsor · 2012-11-01

Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)NCT01690325 · lead sponsor · 2012-09-01

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast CancerNCT01781338 · lead sponsor · 2012-05-01

ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast CancerNCT01779206 · lead sponsor · 2012-05-01

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast CancerNCT01049425 · lead sponsor · 2009-02-05

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEFNCT02115204 · lead sponsor · 2000-06-01

Drugs studied in this sponsor's trials

20 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Women's Cancer Study Group GmbH as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

cyclophosphamide5

docetaxel4

epirubicin4

paclitaxel4

trastuzumab4

pembrolizumab2

pertuzumab2

sacituzumab govitecan2

cyclophosphamide RxCUI 3002 · Lead sponsor in 5 linked trial(s) · 0 currently recruiting 5 trials docetaxel RxCUI 72962 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials epirubicin RxCUI 3995 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials paclitaxel RxCUI 56946 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials trastuzumab RxCUI 224905 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 4 trials pembrolizumab RxCUI 1547545 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials pertuzumab RxCUI 1298944 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials sacituzumab govitecan RxCUI 2360232 · Lead sponsor in 2 linked trial(s) · 1 currently recruiting 2 trials 4 ML pembrolizumab 25 MG/ML Injection [Keytruda] RxCUI 1657751 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial ado-trastuzumab emtansine RxCUI 1371041 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial capivasertib RxCUI 2669967 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial carboplatin RxCUI 40048 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial elacestrant RxCUI 2628469 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial fluorouracil RxCUI 4492 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial gemcitabine RxCUI 12574 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial lapatinib RxCUI 480167 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial methotrexate RxCUI 6851 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial paclitaxel protein-bound RxCUI 486610 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial trastuzumab deruxtecan RxCUI 2267582 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial

Sponsor roles

lead sponsor20

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.